Trial record 1 of 1 for:    IC83 and Pemetrexed
Previous Study | Return to List | Next Study

Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00415636
Recruitment Status : Completed
First Posted : December 25, 2006
Last Update Posted : August 31, 2010
Information provided by:
Eli Lilly and Company

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2010
  Actual Study Completion Date : July 2010

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 February 17, 2018
(Canceled - Date Unknown)
March 26, 2018